湖南省妇科恶性肿瘤质量控制标准解读及实施方案★

Interpretation and implementation plan of quality control for gynecological malignant tumors in Hunan Province★

摘要:

妇科恶性肿瘤是严重威胁中国女性健康的重要疾病，其发病率持续上升，尤其是卵巢癌和宫颈癌的发病率已位居全球之首。以湖南省为例，宫颈癌的发病率已进入省内癌症发病率的前五位，成为影响女性健康的主要问题之一。为应对这一严峻形势，《“健康中国2030”规划纲要》明确提出到2030年将总体癌症5年生存率提高15%的目标。为此，国家癌症中心成立了宫颈癌和卵巢癌质量控制专家委员会，并发布了《中国卵巢癌规范诊疗质量控制指标（2022版）》和《中国宫颈癌规范诊疗质量控制指标（2022版）》。为进一步推动湖南省妇科恶性肿瘤的规范化诊疗及质量控制工作，确保治疗过程的规范化和标准化，提升治疗效果及患者满意度。本文将对上述质量控制指标进行详细解读，并结合湖南省实际情况，提出具体的实施方案。

Abstract:

Gynecological malignancies pose a serious threat to women's health in China, with their incidence rates continuously rising. Notably, the incidence of ovarian cancer and cervical cancer has ranked first in the world. Taking Hunan Province as an example, cervical cancer has ranked among the top five most prevalent cancers in the province, emerging as a major health concern for women. To address this severe situation, the Outline of "Healthy China 2030" Plan has explicitly set the goal of increasing the overall five-year cancer survival rate by 15% by 2030. In response, the National Cancer Center has established the Cervical Cancer and Ovarian Cancer Expert Committee, and issued the Quality Control Index for Standardized Diagnosis and Treatment of Primary Ovarian Cancer in China (2022 Edition) and Quality Control Index for Standardized Diagnosis and Treatment of Cervical Cancer in China (2022 Edition). To further promote standardized diagnosis, treatment, and quality control of gynecological malignancies in Hunan Province, ensure standardized and consistent therapeutic processes, and improve treatment efficacy and patient satisfaction, this article provides a detailed interpretation of the aforementioned quality control indicators. Additionally, it proposes specific implementation strategies tailored to Hunan Province's actual circumstances.